Wells Fargo on Wednesday named the biotech stock a top Q3 tactical pick. An important catalyst looms for Argenx stock.

This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of ...

argenx SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. VYVGART's ongoing US MG penetration and label expansions, including ...

Throughout the last three months, 10 analysts have evaluated argenx (NASDAQ:ARGX), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ...

View argenx SE Sponsored ADR ARGX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2.2 billion in sales last year, argenx has scored FDA approval for a new ...

Argenx has signed on as an early partner to a newly launched initiative from media companies NBCUniversal Local and Digital Health Networks (DHN) that plans to offer healthcare marketing in the form ...

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will ...

Ratings for argenx (NASDAQ:ARGX) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, ...